Literature DB >> 668789

Pharmacokinetic approach to intravenous procainamide therapy.

J J Lima, D R Conti, A L Goldfarb, L H Golden, W J Jusko.   

Abstract

A pharmacokinetic approach was employed to design a dosing regimen for the i.v. use of procainamide (PA) which consisted of a loading infusion given over one hour followed by a maintenance infusion. Therapeutic serum concentrations of PA were achieved in less than 15 min, and toxic serum concentrations were avoided in 12 patients. A mean maximum serum concentration of PA of 5.78 mg/l was obtained with a loading infusion of 16.6 mg/min PA HCl. An average steady-state serum concentration of PA of 5.05 mg/l was obtained with a mean maintenance infusion of 222 mg/hour PA HCl. The total body clearance of PA in slow and fast acetylators averaged 31 and 43 l/h respectively. Use of PA in cardiac patients by i. v. infusion can be safe and effective therapy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 668789     DOI: 10.1007/BF00716367

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  The pharmacokinetics of procainamide in normal subjects using a specific gas chromatographic assay.

Authors:  K J Simons; R H Levy; R E Cutler; G T Christopher; A Lindner
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1975-06

2.  Pharmacokinetics in man of the N-acetylated metabolite of procainamide.

Authors:  J M Strong; J S Dutcher; W K Lee; A J Atkinson
Journal:  J Pharmacokinet Biopharm       Date:  1975-08

3.  Ventricular standstill during the intravenous procaine amide treatment of ventricular tachycardia.

Authors:  M A EPSTEIN
Journal:  Am Heart J       Date:  1953-06       Impact factor: 4.749

4.  Value and hazards of intravenous procaine amide ("pronestyl") therapy.

Authors:  N S STEARNS; E J CALLAHAN; L B ELLIS
Journal:  J Am Med Assoc       Date:  1952-02-02

5.  Use of pronestyl in the treatment of ectopic rhythms; treatment of 98 episodes in 78 patients.

Authors:  K BERRY; E L GARLETT; S BELLET; W I GEFTER
Journal:  Am J Med       Date:  1951-10       Impact factor: 4.965

6.  Antiarrhythmic prophylaxis with procainamide in acute myocardial infarction.

Authors:  J Koch-Weser; S W Klein; L L Foo-Canto; J A Kastor; R W DeSanctis
Journal:  N Engl J Med       Date:  1969-12-04       Impact factor: 91.245

7.  Procainamide dosage schedules, plasma concentrations, and clinical effects.

Authors:  J Koch-Weser; S W Klein
Journal:  JAMA       Date:  1971-03-01       Impact factor: 56.272

8.  The acetylator phenotype of patients with systemic lupus erythematosus.

Authors:  M M Reidenberg; J H Martin
Journal:  Drug Metab Dispos       Date:  1974 Jan-Feb       Impact factor: 3.922

9.  N-Acetylprocainamide levels in patients with end-stage renal failure.

Authors:  T P Gibson; E J Matusik; W A Briggs
Journal:  Clin Pharmacol Ther       Date:  1976-02       Impact factor: 6.875

10.  Comparative evaluation of intravenous phenytoin, procainamide and practolol in the acute treatment of ventricular arrhythmias.

Authors:  E Karlsson; A Kinman; C Sonnhag
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

View more
  4 in total

1.  Effect of procainamide on left ventricular performance in patients with primary myocardial disease.

Authors:  P Geleris; H Boudoulas; S F Schaal; R P Lewis; J J Lima
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

Review 2.  Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

Authors:  P Pentel; N Benowitz
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

3.  Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.

Authors:  J J Lima; D R Conti; A L Goldfarb; W J Tilstone; L H Golden; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

4.  Population pharmacokinetics of procainamide from routine clinical data.

Authors:  T H Grasela; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.